Translating dosage compensation to trisomy 21

Nature

Volumn 500, Issue 7462, 2013, Pages 296-300

  Jiang, Jun ^a   Jing, Yuanchun ^a   Cost, Gregory J ^b   Chiang, Jen Chieh ^a   Kolpa, Heather J ^a   Cotton, Allison M ^a   Carone, Dawn M ^a   Carone, Benjamin R ^a   Shivak, David A ^b   Guschin, Dmitry Y ^b   Pearl, Jocelynn R ^b   Rebar, Edward J ^b   Byron, Meg ^a   Gregory, Philip D ^b   Brown, Carolyn J ^c   Urnov, Fyodor D ^b   Hall, Lisa L ^a   Lawrence, Jeanne B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SANGAMO BIOSCIENCES INC   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DYRK1A PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; XIST PROTEIN; ZINC FINGER NUCLEASE;

CHROMOSOME; DISEASE; DNA; GENE; GENOME; METHYLATION; RNA;

ARTICLE; CHROMOSOME 21; DNA METHYLATION; DOWN SYNDROME; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE INSERTION; GENE SILENCING; HETEROCHROMATIN; HUMAN; HUMAN CHROMOSOME; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; ROSETTE FORMATION; SUPERNUMERARY CHROMOSOME; TRANSGENE; TRISOMY 21; X CHROMOSOME INACTIVATION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 21; DNA METHYLATION; DOSAGE COMPENSATION, GENETIC; DOWN SYNDROME; GENE SILENCING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MICE; MUTAGENESIS, INSERTIONAL; NEUROGENESIS; RNA, LONG UNTRANSLATED; SEX CHROMATIN; X CHROMOSOME INACTIVATION;

EID: 84881668417     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12394     Document Type: Article

References (35)

1. Mégarbané, A. et al. The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet. Med. 11, 611-616 (2009).
2. Gardiner, K. J. Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol. Sci. 31, 66-73 (2010).
3. Prandini, P. et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am. J.Hum. Genet. 81, 252-263 (2007).
4. Haydar, T. F. & Reeves, R. H. Trisomy 21 and early brain development. Trends Neurosci. 35, 81-91 (2012).
5. O'Doherty, A. et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 2033-2037 (2005)
6. Lee, B. & Davidson, B. L. Gene therapy grows into young adulthood: special review issue. Hum. Mol. Genet. 20, R1 (2011).
7. Hall, L. L. et al. X-inactivation reveals epigenetic anomalies in most hESC but identifies sublines that initiate as expected. J. Cell. Physiol. 216, 445-452 (2008).
8. Nazor, K. L. et al. Recurrent variations in DNA methylation in human pluripotent stemcells and their differentiated derivatives. Cell Stem Cell 10, 620-634 (2012).
9. Brown, C. J. et al. The human XIST gene: analysis of a 17 kb inactive X-specificRNA that contains conserved repeats and is highly localized within the nucleus. Cell 71, 527-542 (1992).
10. Clemson, C. M., McNeil, J. A., Willard, H. F. & Lawrence, J. B. XIST RNA paints the inactive X chromosome at interphase: evidence for a novel RNA involved in nuclear/chromosome structure. J. Cell Biol. 132, 259-275 (1996).
11. Heard, E. Delving into the diversity of facultative heterochromatin: the epigenetics of the inactive X chromosome. Curr. Opin. Genet. Dev. 15, 482-489 (2005).
12. Hall, L. L. & Lawrence, J. B. XIST RNA and architecture of the inactive X chromosome: implications for the repeat genome. Cold Spring Harb. Symp. Quant. Biol. 75, 345-356 (2010).
13. Carrel, L. & Willard, H. F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434, 400-404 (2005).
14. Lee, J. T., Strauss, W. M., Dausman, J. A. & Jaenisch, R. A 450 kb transgene displays properties of the mammalian X-inactivation center. Cell 86, 83-94 (1996).
15. Hall, L. L., Clemson, C. M., Byron, M., Wydner, K. & Lawrence, J. B. Unbalanced X;autosome translocations provide evidence for sequence specificity in the association of XISTRNA with chromatin. Hum.Mol. Genet. 11, 3157-3165 (2002).
16. Hall, L. L. et al.AnectopichumanXIST genecaninduce chromosome inactivationin postdifferentiation human HT-1080 cells. Proc. Natl Acad. Sci. USA 99, 8677-8682 (2002).
17. Moehle, E. A. et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc. Natl Acad. Sci. USA 104, 3055-3060 (2007).
18. Urnov, F. D., Rebar, E. J.,Holmes, M. C., Zhang, H.S. & Gregory, P. D.Genome editing with engineered zinc finger nucleases. Nature Rev. Genet. 11, 636-646 (2010).
19. DeKelver, R. C. et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 20, 1133-1142 (2010).
20. Park, I. H. et al. Disease-specific induced pluripotent stemcells. Cell 134, 877-886 (2008).
21. Aït Yahya-Graison, E. et al. Classification of human chromosome 21 geneexpression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 81, 475-491 (2007).
22. Biancotti, J. C. et al. Human embryonic stem cells as models for aneuploid chromosomal syndromes. Stem Cells 28, 1530-1540 (2010).
23. Csankovszki, G., Nagy, A. & Jaenisch, R. Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J. Cell Biol. 153, 773-784 (2001).
24. Cotton, A. M. et al. Chromosome-wide DNA methylation analysis predicts human tissue-specific X inactivation. Hum. Genet. 130, 187-201 (2011).
25. Guidi, S., Ciani, E., Bonasoni, P., Santini, D. & Bartesaghi, R. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol. 21, 361-373 (2011).
26. Shi, Y. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 4, 124ra29 (2012).
27. Lavon, N. et al. Derivation of euploid human embryonic stemcells fromaneuploid embryos. Stem Cells 26, 1874-1882 (2008).
28. Li, L. B. et al. Trisomy correction in down syndromeinduced pluripotent stemcells. Cell Stem Cell 11, 615-619 (2012).
29. Doyon, J. B. et al. Rapid and efficient clathrin-mediated endocytosis revealed in genome-edited mammalian cells. Nature Cell Biol. 13, 331-337 (2011).
30. Miller, J. C. et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nature Biotechnol. 25, 778-785 (2007).
31. Guschin, D. Y. et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol. 649, 247-256 (2010).
32. Urnov, F. D. et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-651 (2005).
33. Byron, M., Hall, L. L. & Lawrence, J. B. A multifaceted FISH approach to study endogenous RNAs and DNAs in native nuclear and cell structures. Curr. Protoc. Hum. Gen. Chapter 4, Unit 4 15 (2013).
34. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).
35. Weber, M. et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nature Genet. 39, 457-466 (2007).